Astellas has said it will book a $170 million ... both in early-stage clinical development – along with DMD gene therapies AT702, AT751 and AT753. The full financial impact of the delay to ...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer ... universal donor cell and gene editing technology it obtained ...

Cancer is well represented in the Astellas Pharma portfolio and pipeline, but the drugmaker has made diversification a key part of its growth strategy. Newer products in its drug lineup include a ...

In light of this, Astellas, a global pharmaceutical company based in Tokyo, Japan, has set a long-term goal of advancing cell and gene therapies for treating eye diseases. Degenerative eye ...

Taysha's cash runway extends to Q4 2026, but likely capital raises could dilute shareholders, adding to downside risk. Click ...

Successful collaborations are built on open communication and a shared commitment to both risks and rewards. These ...

The Key Stargardt Disease Companies in teh market include - Ocugen, Kubota Vision Inc, Nanoscope Therapeutics Inc., RBP4 Pty Ltd, Stargazer Pharmaceuticals, Inc., Belite Bio, Inc, Alkeus ...